

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 02 August 2000 (02.08.00)	
International application No. PCT/KR99/00699	Applicant's or agent's file reference 9FPO-11-03
International filing date (day/month/year) 19 November 1999 (19.11.99)	Priority date (day/month/year) 19 November 1998 (19.11.98)
Applicant HONG, Hyo, Jeong et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

15 June 2000 (15.06.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Olivia RANAIVOJAONA Telephone No.: (41-22) 338.83.38
---	---

COPY FOR IB
PATENT COOPERATION TREATY
PCT

REC'D 09 APR 2001
WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 9FPO-11-03	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/KR99/00699	International filing date (day/month/year) 19 NOVEMBER 1999 (19.11.1999)	Priority date (day/month/year) 19 NOVEMBER 1998 (19.11.1998)
International Patent Classification (IPC) or national classification and IPC IPC7 C07K 16/28, C12N 15/13, C12N 15/63, C12N 15/63		
Applicant KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.


☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 15 JUNE 2000 (15.06.2000)	Date of completion of this report 22 MARCH 2001 (22.03.2001)
Name and mailing address of the IPEA/KR Korean Industrial Property Office Government Complex-Taejon, Dunsan-dong, So-ku, Taejon Metropolitan City 302-701, Republic of Korea Facsimile No. 82-42-472-7140	Authorized officer HAN, Hyun Sook Telephone No. 82-42-481-5596



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/KR99/00699

I. Basis of the report

1. With regard to the elements of the international application:*

- ☐ the international application as originally filed
- ☒ the description:
pages 1 - 31 , as originally filed
pages _____ , filed with the demand
pages _____ , filed with the letter of _____
- ☒ the claims:
pages _____ , as originally filed
pages _____ , as amended (together with any statement) under Article 19
pages _____ , filed with the demand
pages 32 - 34 , filed with the letter of 17 January 2001
- ☒ the drawings:
pages 1 - 11 , as originally filed
pages _____ , filed with the demand
pages _____ , filed with the letter of _____
- ☒ the sequence listing part of the description:
pages 1 - 12 , as originally filed
pages _____ , filed with the demand
pages _____ , filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☒ the claims, Nos. 1
- ☐ the drawings, sheet _____

5. ☐ This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed." and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION

International application No.

PCT/KR99/00699

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	2 - 15	YES
	Claims	NONE	NO
Inventive step (IS)	Claims	2 - 15	YES
	Claims	NONE	NO
Industrial applicability (IA)	Claims	2 - 15	YES
	Claims	NONE	NO

2. Citations and explanations (Rule 70.7)

The document WO 93/16192 A1 is cited in the search report. This publication relates to a humanized antibody capable of binding to a Hepatitis surface antigen, to a pharmaceutical composition which contains the antibody, and to its use in the treatment of Hepatitis and Hepatitis-related disorders. Thus, claims 1 and 15 as originally filed have been anticipated by this state of the art.

However, with the letter of 17 January, 2001 new claims have been filed and the subject matter of the claims 2 to 15 is directed to humanized antibodies specific for HBV surface antigen pre-S1, containing a humanized variable region which comprises specific amino acid sequence described by SEQ ID NOs. 20, 21 or 23. Such humanized antibodies are neither disclosed in the state of art document cited in the search report nor obvious for a person skilled in the art. Therefore, the subject matters of claims 2 to 15, filed with the letter of 17 January, 2001, comply with the requirements of novelty, inventive step and industrial applicability.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 16/28, C12N 15/13, 15/63, A61K 39/395	A1	(11) International Publication Number: WO 00/31141 (43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/KR99/00699 (22) International Filing Date: 19 November 1999 (19.11.99) (30) Priority Data: 1998/49663 19 November 1998 (19.11.98) KR (71) Applicants (for all designated States except US): KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY [KR/KR]; 39-1 Hawolgok-dong, Sungbuk-ku, Seoul 136-130 (KR). KOREA GREEN CROSS CORPORATION [KR/KR]; 227 Gugal-ri, Kiheung-eup, Yongin-si, Kyonggido 449-900 (KR). (72) Inventors; and (75) Inventors/Applicants (for US only): HONG, Hyo, Jeong [KR/KR]; #15-401 Kit Apt., 237 Kajeong-dong, Eusong-ku, Taejon-si 305-350 (KR). RYU, Chun, Jeih [KR/KR]; #136-1203 Hanbit Apt., 99 Oeun-dong, Eusong-ku, Taejon-si 305-333 (KR). HUR, Hyangsuk [KR/KR]; #106-1508 Expo Apt., Jeonmin-dong, Eusong-ku, Taejon-si 305-390 (KR). (74) Agent: LEE, Won-Hee; Suite 805, Sung-ji Heights II, 642-16 Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HUMANIZED ANTIBODY SPECIFIC FOR SURFACE ANTIGEN PRE-S1 OF HBV AND PREPARATION METHOD THEREOF (57) Abstract The present invention relates to humanized antibodies specific for HBV surface antigen pre-S1, which show binding affinity similar to mouse monoclonal antibody and which show remarkably reduced immunogenicity since they have less mouse-derived amino acid residues. Thus, the humanized antibodies of the present invention may be useful for the prevention of HBV infection and for the treatment of hepatitis B.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

REPLACED BY
ART 34 AMDT

What is Claimed is

1. A humanized antibody specific for HBV surface antigen pre-S1, containing humanized heavy and light chain variable regions
- 5 2. The humanized antibody of claim 1, wherein the humanized heavy chain variable region comprises amino acid sequence described by SEQ ID NO: 20
- 10 3. The humanized antibody of claim 1, wherein the humanized heavy chain variable region comprises amino acid sequence described by SEQ ID NO: 21
- 15 4. The humanized antibody of claim 1, wherein the humanized heavy chain variable region comprises an amino acid sequence which is modified from an amino acid residue of SEQ ID NO: 21 by at least one amino acid substitution selected from the group comprising
20 Lys¹² → Val¹², Thr²⁸ → Ala²⁸, Thr³⁰ → Ser³⁰,
Met⁴⁸ → Ile⁴⁸, Arg⁶⁷ → Lys⁶⁷, Val⁶⁸ → Ala⁶⁸,
Met⁷⁰ → Leu⁷⁰, Val⁷⁹ → Ala⁷⁹, and Tyr⁹⁵ → Phe⁹⁵
- 25 5. The humanized antibody of claim 1, wherein the humanized light chain variable region comprises amino acid sequence described by SEQ ID NO: 23

6. A gene encoding humanized heavy chain which contains a humanized heavy chain variable region of claim 2, 3 or 4
- 5
7. The gene of claim 6, wherein the humanized heavy chain variable region comprises amino acid sequence described by SEQ ID NO: 20
- 10
8. The gene of claim 6, wherein the humanized heavy chain variable region comprises amino acid sequence described by SEQ ID NO: 21
- 15
9. A gene encoding humanized light chain which contains a humanized light chain variable region comprising amino acid sequence described by SEQ ID NO: 23
- 20
10. An expression vector containing the gene of claim 6
- 25
11. The expression vector of claim 10, pCMV-HKR127HC, wherein the gene of claim 7 is inserted into pRC/CMV (Accession Number: KCTC 0531BP)
12. The expression vector of claim 10, pCMV-HKR127(III)HC, wherein the gene of claim 8 is

inserted into pRC/CMV (Accession Number: KCTC
0691BP)

13. An expression vector containing the gene of claim
5 9

14. The expression vector of claim 13, pKC-dhfr-HKR127,
wherein the gene of claim 9 is inserted into pCMV-
dhfr (Accession Number: KCTC 0529BP)

10

15. Pharmaceutical composition containing the
humanized antibody of claim 1, which may be
administered in order to prevent HBV infection or
to treat chronic hepatitis B

15

SEQUENCE LISTING

- <110> KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
KOREA GREEN CROSS CORPORATION
- <120> HUMANIZED ANTIBODY SPECIFIC FOR SURFACE ANTIGEN PRE-S1 OF HBV AND
PREPARATION METHOD THEREOF
- <130> 9FPO-11-03
- <150> KR 1998-49663
<151> 1998-11-19
- <160> 28
- <170> KOPATIN 1.5
- <210> 1
<211> 26
<212> DNA
<213> Artificial Sequence
- <220>
<223> synthetic oligonucleotide primer 1
- <400> 1
gagaattcac attcacgatg tacttg 26
- <210> 2
<211> 27
<212> DNA
<213> Artificial Sequence
- <220>
<223> synthetic oligonucleotide primer 2
- <400> 2
ggccccaggc ttcaccactt cagctcc 27

<210> 3
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide primer 3

<400> 3
gtgaagcctg ggcctca 18

<210> 4
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide primer 4

<400> 4
agaactactg aatgcgtagc cagaagc 27

<210> 5
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide primer 5

<400> 5
gcattcagta gttcttgat gaactgg 27

<210> 6
<211> 27
<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 6

<400> 6

aatccgtcca atccactcaa gaccctg

27

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 7

<400> 7

tggattggac ggatttatcc t

21

<210> 8

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 8

<400> 8

ggatttgtct gcagtcagtg tggccttgcc ctggaactt

39

<210> 9

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 9

<400> 9

actgcagaca aatccacgag cacagcctac atggagctc

39

<210> 10

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 10

<400> 10

gtcgtactct cttgcacaga aatagaccgc cgt

33

<210> 11

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 11

<400> 11

gcaagagagt acgacgaggc ttactggggc caa

33

<210> 12

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 12

<400> 12

cggtcgactc atttaccggg agacag

26

<210> 13

<211> 26
<212> DNA
<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 13

<400> 13

caaagcttgg aagcaagatg gattca

26

<210> 14
<211> 36
<212> DNA
<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 14

<400> 14

tggagtttgg gtcacaaaga tatccccaca ggtacc

36

<210> 15
<211> 48
<212> DNA
<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 15

<400> 15

atgacccaaa ctccactttc ttgtcggtt acccctggac aaccagcc

48

<210> 16
<211> 39
<212> DNA
<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 16

<400> 16

caccagatag attagcgct ttggagactg gcctggcctt

39

<210> 17

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 17

<400> 17

ctaattctatc tgggtgtctaa actggactct ggagtcacct

39

<210> 18

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 18

<400> 18

gaagtcgacc taacct

17

<210> 19

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> variable region of heavy chain in mouse KR127 antibody

<400> 19

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala

1

5

10

15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser
 20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys
 85 90 95

Ala Arg Glu Tyr Asp Glu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110

Val Ser Ala
 115

<210> 20

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> variable region of humanized heavy chain HKR127HC(HZI)

<400> 20

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser
 20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
 85 90 95

Ala Arg Glu Tyr Asp Glu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110

Val Ser Ser
 115

<210> 21

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> variable region of humanized heavy chain HKR127HC(HZIII)

<400> 21

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser
 20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Met Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95
 Ala Arg Glu Tyr Asp Glu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110

Val Ser Ser
 115

<210> 22
 <211> 113
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> variable region of light chain in mouse KR127 antibody

<400> 22
 Asp Ile Leu Met Thr Gln Thr Pro Leu Ile Leu Ser Val Thr Ile Gly
 1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
 20 25 30

Asn Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
 35 40 45

Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
 50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ile Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Val Gln Gly
 85 90 95

Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105 110

Arg

<210> 23
 <211> 113
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> variable region of humanized light chain

<400> 23
 Asp Ile Leu Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
 20 25 30
 Asn Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Val Gln Gly
 85 90 95
 Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110

Arg

<210> 24
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> synthetic oligonucleotide primer 24

<400> 24

gttcatccaa gaactggtga aggtgta

27

<210> 25

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 25

<400> 25

agttcttgga tgaactgggt gcgacga

27

<210> 26

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 26

<400> 26

gctcgtggat ttgtctgcag tcattgt

27

<210> 27

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 27

<400> 27

gacaaatcca cgagcacagt ctacatg

27

<210> 28

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 28

<400> 28

gtcgtactct ctcgcacagt aatacac

27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00699

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C 07 K 16/28; C 12 N 15/13, 15/63; A 61 K 39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C 07 K; C 12 N; A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPIL DATABASE, Derwent Publications Ltd., London (GB), PAJ DATABASE, EPO PAJ Database, CA DATABASE, STN Karlsruhe (DE)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 93/16192 A1 (THE WELLCOME FOUNDATION LIMITED) 19 August 1993 (19.08.93), pages 1-5,12-18; claims.	1,15 2-14
A	C.J.RYU et al. "A Humanized Antibody with Specificity for Hepatitis B Surface Antigen", Hum. Antibod. Hybridomas, Vol. 7, No. 3, 1996, pages 113-122., totality.	1-15
A	C.J.RYU et al. "In Vitro Neutralization of Hepatitis B Virus by Monoclonal Antibodies Against the Viral Surface Antigen", Journal of Medical Virology, Vol. 52, 1997, pages 226-233, totality.	1-15

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

27 January 2000 (27.01.00)

Date of mailing of the international search report

29 March 2000 (29.03.00)

Name and mailing address of the ISA/AT

Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/200

Authorized officer

Weniger

Telephone No. 1/53424/341

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 99/00699

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	A1	9316192	19-08-1993	AU	A1	34595/93	03-09-1993
				GB	A0	9202796	25-03-1992
				ZA	A	9300928	10-08-1994

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AMENDED CLAIMS

[received by the International Bureau on 19 May 2000 (19.05.00);
original claims 1-15 replaced by new claims 1-21 (5 pages)]

1. (amended)

5 A vaccine composition for oral administration consisting essentially of protein antigens, in an amount effective to induce an immune response to said antigen, encapsulated in alginate microspheres having a mean diameter from about 0.1 to about 5 μ m.

10 2. The vaccine composition of claim 1, wherein said protein antigen is one or more selected from the group comprising bacterial surface protein antigens, endotoxin or exotoxin antigens, autoantigens, and allergens.

15 3. The vaccine composition of claim 1, wherein said protein antigen is one or more selected from the group comprising a pneumococcal antigen, a *Hemophilus parainfluenza* antigen, a diphtheria antigen, a pertussis antigen, a tetanus antigen, a enterotoxigenic *E. coli* antigen, a dysentery antigen, a cholera antigen, a gonococcus antigen, a influenza virus antigen, B type hepatitis virus antigen, a measles antigen, a smallpox virus antigen, and a rubella antigen.

25 4. The vaccine composition of claim 3, wherein said

pneumococcal protein antigen is one or more selected from group comprising pneumolysin, neuraminidase, autolysin, pneumococcal surface adhesion A(PsaA), and pneumococcal surface protein A(PspA).

5

5. The vaccine composition of claim 1, wherein said vaccine includes additionally immune adjuvants such as cholera toxin, cholera toxin B subunit, *Escherichia coli* Heat labile enterotoxin, muramyl dipeptide or phorbol ester.

10

6. The vaccine composition of claim 5, wherein said immune adjuvant is added to inside or outside of the alginate microsphere.

15

7. (deleted)

8. The vaccine composition of claim 1, wherein said vaccine causes mucosal immunity response.

20

9. (amended)

A process for preparing the vaccine composition of claim 1, comprising the steps of:

- 25
- a) Mixing aliquot of protein antigens or protein antigens including immune adjuvant with a alginate aqueous solution;
 - b) Homogenizing by adding a mixture of the alginate

and protein antigens of step a) to n-octanol containing an emulsifier;

c) Spraying n-octanol solution containing CaCl₂ into the emulsion while stirring the whole emulsion slowly;

d) Adding additional CaCl₂ solution to saturate the emulsion, and curing microspheres;

e) Dehydrating microspheres by addition of dehydrating solvent;

f) Collecting the microspheres on membrane filters and washing with alcohol, and then drying *in vacuo*.

10. The process of claim 9, wherein said protein antigen is one or more selected from the group comprising bacterial surface proteins, endotoxin or exotoxin antigens, autoantigens and allergens.

11. The vaccine composition of claim 9, wherein said protein antigen is one or more selected from the group comprising a pneumococcal antigen, a *Hemophilus parainfluenza* antigen, a diphtheria antigen, a pertussis antigen, a tetanus antigen, a enterotoxigenic *E. coli* antigen, a dysentery antigen, a cholera antigen, a gonococcus antigen, a influenza virus antigen, B type hepatitis virus antigen, a measles antigen, a smallpox virus antigen, and a rubella antigen.

12. The vaccine composition of claim 11, wherein said pneumococcal protein antigen is one more selected from group comprising pneumolysin, neuraminidase, autolysin, pneumococcal surface adhesion A(PsaA), and pneumococcal surface protein A(PspA).

13. The process of claim 9, wherein said vaccine includes additionally immune adjuvants such as cholera toxin, cholera toxin B subunit, *Escherichia coli* Heat labile enterotoxin, muramyldipeptide or phorbol ester.

14. The process of claim 13, wherein said immune adjuvant is added to inside or outside of the microspheres.

15. The process of claim 9, wherein the alginate microspheres solution of step a) is used in 1-5 weight%.

16. The process of claim 9, wherein the emulsifier of step b) is selected from the group comprising HCO-10, HCO-60 and Span-80 which is used in 1-10 weight%.

17. The process of claim 9, wherein the n-octanol containing CaCl_2 in step c) is used in 0.5-2 weight%.

18. The process of claim 9, wherein the CaCl_2 solution

of step d) is used in 5-10 weight%.

19. The process of claim 9, wherein the dehydrating
solvent of step e) is methanol, ethanol, isopropanol or
5 acetone.

20. The process of claim 9, wherein the filter of step
f) is a polyvinylidene difluoride(PVDF) membrane filter
with a pore size between 0.10-0.44 μm .
10

21. The process of claim 9, wherein the alginate
microsphere is approximately 0.1 to 5 μm in diameter.